Navigation Links
Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences
Date:10/25/2010

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences -- CARMIEL, Israel, Oct. 25 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Trade Show News Click to view news release full screen  

Protalix BioTherapeutics to Present at Two Upcoming Healthcare Conferences

 

CARMIEL, Israel, Oct. 25 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-AMEX: PLX, TASE: PLX), announced today that Dr. David Aviezer, the Company's President and Chief Executive Officer, will present at the Oppenheimer 21st Annual Healthcare Conference in New York and the World Orphan Drug Congress 2010 in Geneva. The conference schedule is as follows:Oppenheimer 21st Annual Healthcare ConferenceCorporate Presentation, November 2 at 12:00 PM ETWaldorf Astoria Hotel, New York, NYA webcast of this presentation will be available at www.protalix.com on the event calendar pageWorld Orphan Drug Congress 2010Presentation, November 30 at 9:10 AM CESTCrown Plaza Hotel, Geneva, SwitzerlandAbout ProtalixProtalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary plant cell based expression system.  Protalix's ProCellEx™ presents a proprietary method for the expression of recombinant proteins that Protalix believes will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins in an environment free of mammalian components and viruses.  Protalix is also advancing additional recombinant biopharmaceutical drug development programs.  Taliglucerase alfa is an enzyme replacement therapy in development under a Special Protocol Assessment with the FDA for Gaucher disease. The Company's new drug application (NDA) for taliglucerase alfa has been accepted by the U.S. Food and Drug Administration (FDA) and granted a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

Investor Contact: Marcy NanusThe Trout Group, LLCTelephone: 646-378-2927Email: mnanus@troutgroup.com
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs
2. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
3. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
4. Talecris Biotherapeutics Receives FDA Approval for Gamunex®-C
5. Talecris Biotherapeutics to Report Third Quarter 2010 Financial Results
6. Talecris Biotherapeutics CEO Accepts 2010 Ernst & Young Entrepreneur Of The Year Award on Behalf of Employees and Patients
7. Garnet BioTherapeutics Announces First Patient Treated in Trial of New Therapy for Improvement in Scar Appearance
8. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
9. Oxygen Biotherapeutics, Inc. Announces Approval for NASDAQ Listing
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. Oxygen Biotherapeutics, Inc. Enrolls First Patient in Traumatic Brain Injury Clinical Trial in Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... Sept. 22, 2017 AVACEN Medical (AVACEN) announced ... now successfully helping those with the widespread pain associated ... diagnosed Amanda in Essex, England ... my hair, experiencing no sleep at all, tremendous pain, ... I cannot recommend [the AVACEN 100] enough, how this ...
(Date:9/18/2017)... Pa. and KALAMAZOO, Mich. , Sept. 18, ... , and OptiMed Specialty Pharmacy of ... to offer a strategic hub service that expedites and ... sought-after personal spirometer, Spiro PD 2.0, and wellness management ... spirometer is a medical device used to measure lung ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important to ... Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed a ... or restricted lighting. As such, it eliminates the need to turn on a light ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
Breaking Medicine News(10 mins):